Strumento inattivo

Altre lingue Sunesis Pharmaceuticals, Inc. Nasdaq

Azioni

US8673286014

Altre lingue

Sblocca tutte le notizie su tutte le aziende: non perdere mai più un'opportunità di investimento redditizia!

SUNESIS PHARMACEUTICALS INC : Completion of Acquisition or Disposition of Assets, Material Modification to Rights of Security Holders, Changes in Control or Registrant, Change in Directors or Principal Officers, Amendments to Articles of Inc. or Bylaws; Change in Fiscal Year, Other Events, Financial Statements and Exhibits (form 8-K)	24/02/21
Sunesis Pharmaceuticals, Inc. Announces Executive Changes	24/02/21
SUNESIS PHARMACEUTICALS : MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS (form 10-K)	24/02/21
Sunesis Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2020	24/02/21
Sunesis Pharmaceuticals, Inc.(NasdaqCM:SNSS) dropped from NASDAQ Composite Index	24/02/21
Viracta Therapeutics, Inc. completed the acquisition of Sunesis Pharmaceuticals, Inc. for approximately $100 million in a reverse merger transaction.	24/02/21
SUNESIS PHARMACEUTICALS INC : Change in Directors or Principal Officers, Submission of Matters to a Vote of Security Holders (form 8-K)	23/02/21
SUNESIS PHARMACEUTICALS INC : Other Events (form 8-K)	12/02/21
SUNESIS INVESTOR ALERT By the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Sunesis Pharmaceuticals, Inc. - SNSS	29/12/20
SUNESIS PHARMACEUTICALS INC : Change in Directors or Principal Officers, Other Events (form 8-K)	22/12/20
Sunesis Pharmaceuticals, Inc. Announces Board Changes	22/12/20
Sunesis Pharmaceuticals, Inc. Announces Executive Changes	22/12/20
Sunesis Pharmaceuticals, Inc. Announces Executive Changes	22/12/20
SUNESIS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Sunesis Pharmaceuticals, Inc. - SNSS	03/12/20
Sunesis Pharmaceuticals : to Combine with Viracta Therapeutics in All-Stock Deal	30/11/20
SUNESIS PHARMACEUTICALS INC : Entry into a Material Definitive Agreement, Costs Associated with Exit or Disposal Activities, Change in Directors or Principal Officers, Amendments to Articles of Inc. or Bylaws; Change in Fiscal Year, Regulation FD Disclosure, Financial Statements and Exhibits (form 8-K)	30/11/20
Sunesis Pharmaceuticals and Viracta Therapeutics Announce Definitive Merger Agreement	30/11/20
Viracta Therapeutics, Inc. executed the Offer Letter to acquire Sunesis Pharmaceuticals, Inc. in a reverse merger transaction	30/11/20
Sunesis Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter Ended September 30, 2020	16/11/20
SUNESIS PHARMACEUTICALS : Management's Discussion and Analysis of Financial Condition and Results of Operations (form 10-Q)	16/11/20

Non ci sono risultati per questa ricerca

Tutte le notizie Raccomandazione analisti Eventi più importanti Insiders Resoconti Comunicati stampa Pubblicazioni ufficiali Altre lingue Idee di trading Articoli MarketScreener Analisi MarketScreener

Altre lingue Sunesis Pharmaceuticals, Inc. Nasdaq

Azioni

US8673286014

Altre lingue

Filtri